Actively Recruiting

Phase 4
Age: 18Years - 75Years
All Genders
NCT05593055

Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension

Led by Brigham and Women's Hospital · Updated on 2026-04-06

75

Participants Needed

1

Research Sites

227 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The investigators' goal is to show that in hypertensive men and women with left ventricular hypertrophy (LVH) treatment with a mineralocorticoid receptor (MR) antagonist, versus a thiazide-like diuretic, will improve coronary microvascular function and cardiac efficiency, which will associate with improvements in LV structure and function. The investigators will achieve this through a randomized, controlled, basic experimental study involving humans (BESH).

CONDITIONS

Official Title

Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • History of hypertension with seated systolic BP <180 mmHg and diastolic <110 mmHg if on antihypertensives
  • History of hypertension with seated systolic BP 141-200 mmHg and/or diastolic BP 90-114 mmHg if not on antihypertensives
  • Left ventricular hypertrophy confirmed by echocardiogram (men: septum thickness ≥12mm; women: septum thickness ≥11mm)
  • Treated hypothyroidism allowed
  • Pre-diabetes or diabetes controlled by diet, exercise, and/or metformin allowed
Not Eligible

You will not qualify if you...

  • Use of MR antagonist (eplerenone, spironolactone, or finerenone) or amiloride within the past year
  • Orthostatic hypotension
  • Major medical illness including uncontrolled diabetes mellitus (Hemoglobin A1c >7.5)
  • Left ventricular ejection fraction <40%
  • New York Heart Association class III to IV heart failure or unstable angina
  • History in prior 6 months of Q-wave myocardial infarction, stroke, transient ischemic attack, percutaneous transluminal coronary angioplasty, or coronary artery bypass graft
  • History of secondary hypertension
  • Known genetic cardiomyopathy
  • Renal disease (serum creatinine >1.5 mg/dL for men and >1.3 mg/dL for women)
  • Hepatic disease
  • Bronchospastic lung disease
  • Alcohol or substance abuse
  • Hormone replacement therapy
  • Abnormal values for electrolytes, liver enzymes, or thyroid stimulating hormone
  • Pregnancy or lactation
  • Individuals younger than 18 or older than 75 years

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Brigham and Women's Hospital

Boston, Massachusetts, United States, 02115

Actively Recruiting

Loading map...

Research Team

G

Gail K Adler, MD, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

BASIC_SCIENCE

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here